A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Affiliations

• ¹ University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. Joshua_Zeidner@med.unc.edu.
• ² University of Kansas Medical Center, Kansas City, KS, USA.
• ³ University of Iowa, Iowa City, IA, USA.
• ⁴ Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
• ⁵ Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA.
• ⁶ Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
• ⁷ Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
• ⁸ Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
• ⁹ Columbia University Irving Medical Center, New York, NY, USA.
• ¹⁰ Princess Margaret Cancer Centre, Toronto, ON, Canada.
• ¹¹ Ochsner Medical Center, New Orleans, LA, USA.
• ¹² Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
• ¹³ Hospital San Pedro de Alacantra, Caceres, Spain.
• ¹⁴ Cancer Treatment Centers of America, Phoenix, AZ, USA.
• ¹⁵ Mayo Clinic, Rochester, MN, USA.
• ¹⁶ Hospital Universitario Central de Asturias, Asturias, Spain.
• ¹⁷ Fred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
• ¹⁸ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
• ¹⁹ University Hospitals Bristol, Bristol, UK.
• ²⁰ Department of Medical and Molecular Genetics, King's College, London, UK.
• ²¹ Hospital Clinico Universitario de Salamanca, Salamanca, Spain.
• ²² University of Utah, Salt Lake City, UT, USA.
• ²³ Hospital Universitario Politecnico La Fe, Valencia, Spain.
• ²⁴ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.